| Ytd | -43.48% | |
| 1y | 18.97% |
| Open | 5.08 | Prev Close | 5.02 | Low | 4.86 | High | 5.08 | Mkt Cap | 299.52M |
| Vol | 360.81K | Avg Vol | 964.95K | EPS | -2.70 | P/E | -1.84 | Forward P/E | 23.40 |
| Beta | 0.64 | Short Ratio | 4.85 | Inst. Own | 78.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 5.77 | 200-d Avg | 6.52 | 1yr Est | 10.43 |
VNDA News
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-s
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Arrowstreet Capital Limited Partnership purchased a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:
Vanda Pharmaceuticals (NASDAQ: VNDA) reported second-quarter 2026 revenue of $50.5 million, down 4%
Vanda Pharmaceuticals NASDAQ: VNDA reported second-quarter 2026 revenue of $50.5 million, down 4% fr
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Cons
Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%
Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceutical
This marks the first time the EMA has granted orphan drug designation recognition for a drug to trea
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ann
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ann
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeli
WASHINGTON, May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today anno
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.82 per share versus the Zacks Cons
Fanapt ® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-b
The mean of analysts' price targets for Vanda (VNDA) points to a 105% upside in the stock. While thi
Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 4, 2026 /PRNewswire/ -- Vanda
Top Wall Street analysts changed outlook on top names. See analyst ratings page for full view. EQIX
Stock futures are in red early morning on New Year's Eve, after markets ended lower on Tuesday,
Stock futures down, ORIS to acquire controlling stake in tea company, VNDA gets FDA approval, ELLO p
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positi
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quart
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
On Tuesday, 647 companies set new 52-week lows.
On Tuesday, 164 companies achieved new lows for the year.
On Wednesday, 59 companies achieved new lows for the year.
During Thursday's session, 92 stocks hit new 52-week lows.